The beginning of the end for semaglutide

[anonymous]

CONCLUSIONS
In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919. opens in new tab.)

about time Novo falls flat on it face.

 

[anonymous]

It also was superior to degludec in the Surpass trial. Ruh-row. I know we don’t promote Tresiba but it will affect overalll NNI bottom line cutting into that insulin profit -
dusting off my resume

 

[anonymous]

It also was superior to degludec in the Surpass trial. Ruh-row. I know we don’t promote Tresiba but it will affect overalll NNI bottom line cutting into that insulin profit -
dusting off my resume

In. SURPASS 3. Tirzepatide= Better A!C -lower hypos - lost weight.

 

[anonymous]

This will be another very large nail in the Novo coffin!!! I do have faith in our ET to lead us through though. More diversity and inclusion focus will do the trick

 

[anonymous]

Looks like the new Lilly reps just got out of their POA meeting.

You do realize that all you did was add another agent to a GLP-1, right? Which can be done for much cheaper.

 

[anonymous]

It also was superior to degludec in the Surpass trial. Ruh-row. I know we don’t promote Tresiba but it will affect overalll NNI bottom line cutting into that insulin profit -
dusting off my resume

0/10, you clearly don't work here.

 

[anonymous]

Putting the No in No vo.

0/10, you clearly don't work here.